Clinical Trial Update: Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluated Ozurdex 0.7 mg for improving bevacizumab efficacy in non-ischemic central retinal vein occlusion. The trial has completed and posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Non-ischemic Central Retinal Vein Occlusion

Drugs mentioned

• Bevacizumab (bevacizumab)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Texas Retina Associates | Conditions: Non-Ischemic Central Retinal Vein Occlusion | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-10-18